Akt and mRNA translation by interferons

Cell Cycle

Volumn 7, Issue 14, 2008, Pages 2112-2116

  Kaur, Surinder ^a   Katsoulidis, Efstratios ^a   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Akt; Antiviral; Interferon; mRNA translation; Signaling

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERFERON; INTERFERON RECEPTOR; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B BETA; STAT PROTEIN;

CELL MEMBRANE; CELL NUCLEUS; CYTOPLASM; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; POSITIVE FEEDBACK; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

EID: 47749140740     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.14.6258     Document Type: Review

References (66)

1. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56:727-77.
2. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-64.
3. Parmar S, Platanias LC. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15:431-9.
4. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-20.
5. Darnell JE. Stats and gene regulation. Science 1997; 277:1630-5.
6. Platanias LC. Mechanisms of type I and type II interferon-mediated signaling. Nat Rev Immunol 2005; 5:375-86.
7. Baker SJ, Rane SG, Reddy E P. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26:6724-37.
8. Platanias LC, Fish EN. Signalling pathways activated by interferons. Exp Hemtaol 1999; 27:1583-92.
9. Platanias LC. Introduction: interferon signals: what is classical and what is nonclassical? J Interferon Cytokine Res 2005; 25:732.
10. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 2003; 98:129-42.
11. Uddin S, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, Young PR, Fish EN, Platanias LC. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem 1999; 274:30127-31.
12. Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Platanias LC. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 2000; 275:27634-40.
13. Li Y, Sassano A, Majchrzak B, Deb DK, Levy DE, Gaestel M, Nebreda AR, Fish EN, Platanias LC. Role of p38alpha MAP kinase in type I interferon signaling J Biol Chem 2004; 279:970-9.
14. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC. The p38 MAPK pathway mediates the growth inhibitory effects of interferon in BCR-ABL-expressing cells. J Biol Chem 2001; 276:28570-77.
15. Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanias LC. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002; 277:14408-16.
16. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, Uddin S, Rahman A, Fish EN, Platanias LC. Activation of protein kinase C delta by IFNgamma. J Immunol 2003; 171:267-73.
17. 2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFNgamma. Proc Natl Acad Sci USA 2002; 99:5971-6.
18. Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 2003; 100:14742-7.
19. Chang HM, Paulson M, Holko M, Rice CM, Williams BR, Marié I, Levy DE. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 2004; 101:9578-83.
20. Sakamoto S, Potla R, Larner AC. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem 2004; 279:40362-7.
21. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999; 68:965-1014.
22. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8:179-83.
23. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007; 12:487-502.
24. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45.
25. Du K, Tsichlis PN. Regulation of the Akt kinase by interacting proteins. Oncogene 2005; 24:7401-9.
26. Cheng GZ, Zhang W, Wang LH. Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 2008; 68:957-60.
27. Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 2008; 8:19-26.
28. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001; 15:2203-8.
29. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG, Hay N. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003; 17:1352-65.
30. Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, Michaelis T, Frahm J, Hemings BA. Essential role of protein kinase B (PKB/Akt3) in postnatal brain development but not in glucose homeostasis. Development 2005; 132:2943-54.
31. Dummler B, Tschopp O, Hynx D, Yang ZZ, Dirnhofer S, Hemmings BA. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol 2006; 26:8042-51.
32. Yang ZZ, Tschopp O, Di-Poi N, Bruder E, Baudry A, Dümmler B, Wahli W, Hemmings BA. Dosage-dependent effects of Akt1/protein kinase Bα (PKBα) and Akt3/PKBγ on thymus, skin, and cardiovascular and nervous system development in mice. Mol Cell Biol 2005; 25:10407-18.
33. Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, Byzova TV. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 2005; 11:1188-96.
34. Maroulakou IG, Oemler W, Naber S P, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007; 67:167-77.
35. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
36. Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream Cell 2007; 129:1261-74.
37. Uddin S, Yenush L, Sun XJ, Sweet ME, White M F, Platanias LC. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J Biol Chem 1995; 270:15938-41.
38. Uddin S, Fish EN, Sher DA, Gardziola C, White M F, Platanias LC. Activation of the phosphatidylinositol 3-kinase serine kinase by IFNalpha. J Immunol 1997; 158:2390-7.
39. Platanias LC, Uddin S, Yetter A, Sun XJ, White M F. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. J Biol Chem 1996; 271:278-82.
40. Burfoot MS, Rogers NC, Watling D, Smith JM, Pons S, Paonessaw G, Pellegrini S, White M F, Kerr IM. Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons. J Biol Chem 1997; 272:24183-90.
41. Uddin S, Fish EN, Sher D, Gardziola C, Colamonici OR, Kellum M, Pitha PM, White MF, Platanias LC. The IRS-pathway operates distinctively from the Stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-alpha receptors. Blood 1997; 90:2574-82.
42. Nguyen H, Ramana C V, Bayes J, Stark GR. Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem 2001; 276:33361-8.
43. Van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006; 25:361-72.
44. Van Boxel-Dezaire AH, Stark GR. Cell type-specific signaling in response to interferon-gamma. Curr Top Microbiol Immunol 2007; 316:119-54.
45. Venkatesan BA, Mahimainathan L, Ghosh-Choudhury N, Gorin Y, Bhandari B, Valente AJ, Abboud HE, Choudhury GG. PI 3 kinase-dependent Akt kinase and PKCepsilon independently regulate interferon-gamma-induced STAT1alpha serine phosphorylation to induce monocyte chemotactic protein-1 expression. Cell Signal 2006; 18:508-18.
46. Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanias LC. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002; 277:14408-16.
47. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, Uddin S, Rahman A, Fish EN, Platanias LC. Activation of protein kinase C delta by IFNgamma. J Immunol 2003; 171:267-73.
48. Guo J, Hui DJ, Merrick WC, Sen GC. A new pathway of translational regulation mediated by eukaryotic initiation factor 3. EMBO J 2000; 19:6891-9.
49. Friedman RM, Metz DH, Esteban RM, Tovell DR, Ball LA, Kerr IM. Mechanism of interferon action: inhibition of viral messenger ribonucleic acid translation in L-cell extracts. J Virol 1972; 10:1184-98.
50. Samuel CE. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991; 183:1-11.
51. Lekmine F, Uddin S, Sassano A, Parmar S, Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN, Platanias LC. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 2003; 278:27772-80.
52. Lekmine F, Sassano A, Uddin S, Smith J, Majchrzak B, Brachmann SM, Hay N, Fish EN, Platanias LC. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 2004; 295:173-82.
53. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 1997; 16:3693-704.
54. Jefferies HB, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci USA 1994; 91:4441-5.
55. Stolovich M, Tang H, Hornstein E, Levy G, Cohen R, Bae SS, Birnbaum MJ, Meyuhas O. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol Cell Biol 2002; 22:8101-13.
56. Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, Baker D P, Petroulakis E, Hay N, Sonenberg N, Fish EN, Platanias LC. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 2007; 282:1757-68.
57. Kaur S, Sassano A, Dolniak B, Joshi S, Majchrzak-Kita B, Baker D P, Hay N, Fish EN, Platanias LC. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci USA 2008; 105:4808-13.
58. Gough NR. Akt Connects Interferon to Translation. Sci Signal 2008; 1:119.
59. Colina R, Costa-Mattioli M, Dowling RJ, Jaramillo M, Tai LH, Breitbach CJ, Martineau Y, Larsson O, Rong L, Svitkin Y V, Makrigiannis A P, Bell JC, Sonenberg N. Translational control of the innate immune response through IRF-7. Nature 2008; 452:323-8.
60. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, Zhivotovsky B, Leibiger I, Grandér D, Pokrovskaja K. Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 2004; 279:24152-62.
61. Fang P, Hwa V, Rosenfeld RG. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res 2006; 312:1229-39.
62. Rosner D, Stoneman V, Littlewood T, McCarthy N, Figg N, Wang Y, Tellides G, Bennett M. Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am J Pathol 2006; 168:2054-63.
63. Lei H, Furlong PJ, Ra JH, Mullins D, Cantor R, Fraker DL, Spitz FR. AKT activation and response to interferon-beta in human cancer cells. Cancer Biol Ther 2005; 4:709-15.
64. Barca O, Ferré S, Seoane M, Prieto JM, Lema M, Señarís R, Arce VM. Interferon beta promotes survival in primary astrocytes through phosphatidylinositol 3-kinase. J Neuroimmunol 2003; 139:155-9.
65. Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 2008; 15:88-94.
66. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25:6416-22.